BioInsights - Accelerate your development & understanding of viral & non-viral drug delivery vectors: from proof of concept to drug product manufacture

Accelerate your development & understanding of viral & non-viral drug delivery vectors: from proof of concept to drug product manufacture

Cell & Gene Therapy Insights 2022; 8(9), 1195

DOI: 10.18609/cgti.2022.177

Published: 12 October 2022
FastFacts


Watch the video or view the poster to learn:

  • Which analytical technologies can be used to characterize and optimize viral and lipid-based formulations 
  • How to analyse specific characteristics of AAV delivery vectors and lipid nanoparticles (LNPs)
  • The importance of applying orthogonal analytical techniques and which techniques are complementary
  • Strengths and weaknesses of various characterization techniques for the development of drug delivery vectors

Hanna Jankevics Jones studied physics at the Royal institute of Technology (Stockholm, Sweden) followed by a PhD in Physical Chemistry at the Swiss Federal Institute of Technology Lausanne (Switzerland). She joined Malvern Panalytical (formerly Malvern Instruments) in 2008 as a Product Technical Specialist for biophysical characterization. In 2013, Hanna moved into R&D, where, as Principal Applications Scientist, she set up and mentored the team responsible for developing new applications and instruments across all product ranges. In 2017, Hanna became product owner for the Zetasizer Advance range of light scattering instruments, overseeing the development of new hardware and software. In 2019 Hanna moved to a strategic marketing role, focusing on complex drug product development.